hydroxyproline has been researched along with tetrathiomolybdate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brewer, GJ; Dick, R; Olivarez, L; Phan, SH; Ullenbruch, MR | 1 |
| Askari, FK; Brewer, GJ; Dick, R; Mao, M | 1 |
2 other study(ies) available for hydroxyproline and tetrathiomolybdate
| Article | Year |
|---|---|
Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Bleomycin; Body Weight; Ceruloplasmin; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Hydroxyproline; Lung; Mice; Mice, Inbred CBA; Molybdenum; Pulmonary Fibrosis | 2003 |
Tetrathiomolybdate therapy protects against concanavalin a and carbon tetrachloride hepatic damage in mice.
Topics: Alanine Transaminase; Animals; Carbon Tetrachloride Poisoning; Chelating Agents; Concanavalin A; Copper; Cytokines; Hydroxyproline; Liver; Mice; Mice, Inbred BALB C; Mice, Inbred CBA; Molybdenum | 2004 |